2-(4-Hydroxyphenyl)-3-methyl-1-[(4-methylphenyl)methyl]indol-5-ol | 104599-08-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-(4-Hydroxyphenyl)-3-methyl-1-[(4-methylphenyl)methyl]indol-5-ol
• CAS: 104599-08-8
• 化学式: C₂₃H₂₁NO₂
• 分子量: 343.425
• InChiKey: LDCQDPUSQNMDED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  45.4
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  乙酸酐 、 2-(4-Hydroxyphenyl)-3-methyl-1-[(4-methylphenyl)methyl]indol-5-ol 在 吡啶 作用下， 反应 2.0h， 生成 [4-[5-Acetyloxy-3-methyl-1-[(4-methylphenyl)methyl]indol-2-yl]phenyl] acetate
  参考文献：
  名称：

  2-Phenylindoles. Effect of N-benzylation on estrogen receptor affinity, estrogenic properties, and mammary tumor inhibiting activity

  摘要：

  Hydroxy-2-phenylindoles carrying substituted benzyl groups and similar substituents at the nitrogen were synthesized and tested for their ability to displace estradiol from its receptor. All of the derivatives tested exhibited high binding affinities for the calf uterine estrogen receptor, with RBA values ranging from 0.55 to 16 (estradiol 100). The mouse uterine weight tested revealed only low estrogenicity for this class of compounds. Several derivatives showed antiestrogenic activity with a maximum inhibition of estrone-stimulated uterine growth of 40%. Two of the compounds (6c, 21c) were tested for antitumor activity in dimethylbenanthracene- (DMBA-) induced estrogen-dependent rat mammary tumors. Only the 4-cyanobenzyl derivative 21c was active. After 4 weeks of treatment with 12 mg/kg (6 times/week), the average tumor area was decreased by 57% (control +204%). In vitro, an inhibitory effect of 21b was only observed with hormone-sensitive MCF-7 breast cancer cells but not with hormone-independent MDA-MB 231 cells. These results make a mode of action involving the estrogen receptor system likely.

  DOI：

  10.1021/jm00384a022
• 作为产物：
  描述：

  5-甲氧基-2-(4-甲氧基苯基)-3-甲基-1H-吲哚 在 三溴化硼 、 sodium hydride 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成 2-(4-Hydroxyphenyl)-3-methyl-1-[(4-methylphenyl)methyl]indol-5-ol
  参考文献：
  名称：

  2-Phenylindoles. Effect of N-benzylation on estrogen receptor affinity, estrogenic properties, and mammary tumor inhibiting activity

  摘要：

  Hydroxy-2-phenylindoles carrying substituted benzyl groups and similar substituents at the nitrogen were synthesized and tested for their ability to displace estradiol from its receptor. All of the derivatives tested exhibited high binding affinities for the calf uterine estrogen receptor, with RBA values ranging from 0.55 to 16 (estradiol 100). The mouse uterine weight tested revealed only low estrogenicity for this class of compounds. Several derivatives showed antiestrogenic activity with a maximum inhibition of estrone-stimulated uterine growth of 40%. Two of the compounds (6c, 21c) were tested for antitumor activity in dimethylbenanthracene- (DMBA-) induced estrogen-dependent rat mammary tumors. Only the 4-cyanobenzyl derivative 21c was active. After 4 weeks of treatment with 12 mg/kg (6 times/week), the average tumor area was decreased by 57% (control +204%). In vitro, an inhibitory effect of 21b was only observed with hormone-sensitive MCF-7 breast cancer cells but not with hormone-independent MDA-MB 231 cells. These results make a mode of action involving the estrogen receptor system likely.

  DOI：

  10.1021/jm00384a022

文献信息

• [EN] FUSED IMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF<br/>[FR] DÉRIVÉ IMIDE FUSIONNÉ, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION MÉDICALE<br/>[ZH] 稠合酰亚胺类衍生物、其制备方法及其在医药上的应用
  申请人：JIANGSU HENGRUI MEDICINE CO

  公开号：WO2021143816A1

  公开（公告）日：2021-07-22

  涉及稠合酰亚胺类衍生物、其制备方法及其在医药上的应用。具体而言，涉及一种通式(IM)所示的新型稠合酰亚胺类小脑蛋白(cereblon)E3泛素连接酶蛋白质结合的配体化合物和包含其的蛋白降解靶向嵌合体(PROTACs)化合物，其制备方法，及其在医药上的应用。通式(IM)中各基团的定义与说明书中的定义相同。
• [EN] BICYCLIC IMIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN MEDICINE<br/>[FR] DÉRIVÉ IMIDE BICYCLIQUE, SON PROCÉDÉ DE PRÉPARATION ET SON APPLICATION EN MÉDECINE<br/>[ZH] 并环酰亚胺类衍生物、其制备方法及其在医药上的应用
  申请人：JIANGSU HENGRUI MEDICINE CO

  公开号：WO2021143822A1

  公开（公告）日：2021-07-22

  涉及并环酰亚胺类衍生物、其制备方法及其在医药上的应用。具体而言，涉及一种通式(IM)所示的新型并环酰亚胺类小脑蛋白(cereblon)E3泛素连接酶蛋白质结合的配体化合物和包含其的蛋白降解靶向嵌合体(PROTACs)化合物，其制备方法，及其在医药上的应用。通式(IM)中各基团的定义与说明书中的相同。
• VON ANGERER E.; STROHMEIER J., J. MED. CHEM., 30,(1987) N 1, 131-136
  作者：VON ANGERER E.、 STROHMEIER J.

  DOI：——

  日期：——